Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid ...

There aren't many biotechs that are more exciting than Viking Therapeutics (NASDAQ: VKTX) right now. Thanks to its clinical-stage candidate for weight loss, there's a real chance that this competitor ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

Los Angeles Capital Management LLC trimmed its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by ...

About Viking Therapeutics, Inc. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...

So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific pharmaceutical operation in my eyes. In addition to the unprecedented growth ...

Viking Therapeutics is a clinical-stage biotech that's looking to compete with Lilly in weight loss treatment. Viking recently revealed plans to develop an obesity treatment that could be superior ...

Investors with a lot of money to spend have taken a bearish stance on Viking Therapeutics VKTX. And retail traders should know. We noticed this today when the trades showed up on publicly ...

Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.

In trading on Tuesday, shares of Viking Therapeutics Inc (Symbol: VKTX) crossed below their 200 day moving average of $61.13, changing hands as low as $58.39 per share. Viking Therapeutics Inc ...